<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01320709</url>
  </required_header>
  <id_info>
    <org_study_id>14835</org_study_id>
    <secondary_id>2010-021195-28</secondary_id>
    <nct_id>NCT01320709</nct_id>
  </id_info>
  <brief_title>Effect of Piroxicam on Ovulation</brief_title>
  <official_title>Single-center, Randomized, Placebo-controlled, Double-blind, Parallel Group Study to Evaluate Whether a Single-dose of Either 20 mg Piroxicam, 40 mg Piroxicam or 80 mg Piroxicam Shows an Effect on Ovulation After the Onset of LH Surge Compared to Placebo in Healthy Young Women</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bayer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bayer</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      In this study the effect of piroxicam on the ovulation will be evaluated. Therefore piroxicam&#xD;
      will be administered as a single-dose after onset of LH surge (luteinizing hormone, hormone&#xD;
      which triggers ovulation).&#xD;
&#xD;
      Additionally blood levels of endogenous hormones (hormones produced by your body) will be&#xD;
      measured and transvaginal ultrasound examinations will be conducted at regular intervals. In&#xD;
      addition the concentration of piroxicam in blood will be determined in regular intervals.&#xD;
&#xD;
      With regards to the tolerability of the study drug subjects will be asked regularly how they&#xD;
      feel.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2011</start_date>
  <completion_date type="Actual">May 2012</completion_date>
  <primary_completion_date type="Actual">March 2012</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Effect of piroxicam on ovulation (delay or inhibition) when given after the onset of LH surge</measure>
    <time_frame>after 2 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>course of follicle sizes</measure>
    <time_frame>after 2 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>course of gonadotropins (follicle-stimulating hormone [FSH], LH) and ovarian steroids (estradiol [E2], progesterone)</measure>
    <time_frame>after 2 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Concentration-times courses of piroxicam</measure>
    <time_frame>after 2 months</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">72</enrollment>
  <condition>Contraception, Postcoital</condition>
  <arm_group>
    <arm_group_label>Arm 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 3</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Piroxicam ( BAYl1902)</intervention_name>
    <description>Single dose of 20 mg piroxicam (i.e., 1 piroxicam capsule + 3 placebo capsule)</description>
    <arm_group_label>Arm 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Piroxicam ( BAYl1902)</intervention_name>
    <description>Single dose of 40 mg piroxicam (i.e., 2 piroxicam capsules + 2 placebo capsule)</description>
    <arm_group_label>Arm 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Single dose of placebo (i.e., 4 placebo capsules)</description>
    <arm_group_label>Arm 3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Piroxicam ( BAYl1902)</intervention_name>
    <description>Single dose of 80 mg piroxicam (i.e., 4 piroxicam capsules)</description>
    <arm_group_label>Arm 4</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Signed informed consent available before any study specific tests or procedures are&#xD;
             performed&#xD;
&#xD;
          -  Healthy female subject&#xD;
&#xD;
          -  Age: 18 to 35 years (inclusive) at the first screening visit&#xD;
&#xD;
          -  Body mass index (BMI ): 18-30 kg/mÂ² (inclusive) at the first screening visit&#xD;
&#xD;
          -  Confirmation of the subject's health insurance coverage prior to the first screening&#xD;
             visit&#xD;
&#xD;
          -  Willingness to use non-hormonal methods of contraception during the study&#xD;
&#xD;
          -  Ability to understand and follow study-related instructions&#xD;
&#xD;
          -  Adequate venous access&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Incompletely cured pre-existing diseases for which it can be assumed that the&#xD;
             absorption, distribution, metabolism, elimination, and effects of the study drugs will&#xD;
             not be normal&#xD;
&#xD;
          -  Hypersensitivity to the active substance or skin reactions (irrespective of severity)&#xD;
             to piroxicam, non-steroidal anti-inflammatory drugs or other medicinal products in the&#xD;
             past&#xD;
&#xD;
          -  History or presence of inflammatory diseases of the gastrointestinal tract,&#xD;
             gastrointestinal bleeding, ulcers or perforation&#xD;
&#xD;
          -  Regular intake of medication other than hormonal contraceptives&#xD;
&#xD;
          -  Clinically relevant findings in the gynecological examination including transvaginal&#xD;
             ultrasound (TVU)&#xD;
&#xD;
          -  Clinically relevant findings in the physical examination, especially signs of bleeding&#xD;
             diathesis or heart failure&#xD;
&#xD;
          -  Time point &quot;onset of LH surge&quot; in the pre-treatment cycle not determinable&#xD;
&#xD;
          -  Time point &quot;ovulation&quot; in the pre-treatment cycle not determinable&#xD;
&#xD;
          -  Lacking suitability for frequent TVU examinations&#xD;
&#xD;
          -  History or presence of suffering from hay fever&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>35 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bayer Study Director</last_name>
    <role>Study Director</role>
    <affiliation>Bayer</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Berlin</city>
        <zip>13353</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>December 2014</verification_date>
  <study_first_submitted>March 21, 2011</study_first_submitted>
  <study_first_submitted_qc>March 21, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 22, 2011</study_first_posted>
  <last_update_submitted>July 9, 2015</last_update_submitted>
  <last_update_submitted_qc>July 9, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 10, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Emergency contraception</keyword>
  <keyword>Contraception</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Piroxicam</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

